Development of malignancy following lung transplantation

Transplantation

Volumn 81, Issue 4, 2006, Pages 547-551

  Amital, Anat ^a   Shitrit, David ^a   Raviv, Yael ^a   Bendayan, Daniele ^a   Sahar, Gideon ^a   Bakal, Ilana ^a   Kramer, Mordechai R ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Lungs; Malignancies; Transplants

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METHYLPREDNISOLONE; MITOMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TSUKUBAENOLIDE; VALGANCICLOVIR; VINBLASTINE;

ADULT; ASPERGILLOSIS; BASAL CELL CARCINOMA; BLADDER CARCINOMA; BRONCHIOLITIS OBLITERANS; CANCER RISK; COLON CANCER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYDRATION; ISRAEL; KAPOSI SARCOMA; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PNEUMOCYSTOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; REVIEW; SKIN CANCER; SMOKING; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; TRANSITIONAL CELL CARCINOMA;

ADULT; FEMALE; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 33644615634     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000195774.26382.34     Document Type: Review

References (48)

1. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89(7): 1221-1227.
2. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-First Official Adult Lung and Heart-Lungs Transplant Report-2004. J Heart Lung Transplant 2004; 23(7): 804-815.
3. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12(6 Pt 2): S328-336.
4. Freedman LS, Barchana M, Al-Kayed S, et al. A comparison of population-based cancer incidence rates in Israel and Jordan. Eur J Cancer Prev 2003; 12(5): 359-365.
5. Israeli Health Ministry. Israel National Cancer Registry. Available at: www.health.gov.il/icr. Accessed January 25, 2006.
6. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61(5): 715-721.
7. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients. Risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102(19 Suppl 3): III222-227.
8. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124(4): 1242-1249.
9. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11(4): 753-759.
10. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323(25): 1767-1769.
11. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20(10): 1044-1053.
12. De Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003; 75(2): 367-371.
13. Ahmed Z, Marshall MB, Kucharczuk JC. Lung cancer in transplant recipients: a single-institution experience. Arch Surg 2004; 139(8): 902-906.
14. McAdams HP, Erasmus JJ, Palmer SM. Complications (excluding hyperinflation) involving the native lung after single-lung transplantation: incidence, radiologic features, and clinical importance. Radiology 2001; 218(1): 233-241.
15. Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with non-melanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49(3): 397-406.
16. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348(17): 1681-1691.
17. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Relations between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991; 325: 843-848.
18. Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65(9): 1270-1272.
19. Gjersvik P, Hansen S, Moller B, et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients? Transpl Int 2000; 13 Suppl 1: S380-381.
20. Naldi L, Fortina AB, Lovati S, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000; 70(10): 1479-1484.
21. Ferrandiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995; 33(4): 590-596.
22. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(2 Pt 1): 177-186.
23. Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979; 67(5): 759-765.
24. Woodle ES, Hanaway M, Buell J, et al. Israel Penn International Transplant Tumor Registry. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry. Transplant Proc 2001; 33(7-8): 3660-3661.
25. FargeD. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993; 2(6): 339-343.
26. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64(5): 669-673.
27. Parravicini C, Olsen SJ, Capra M, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997; 90(7): 2826-2829.
28. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339(19): 1358-1363.
29. Luppi M, Barozzi P, Guaraldi G, et al. Human herpesvirus 8-associated diseases in solid-organ transplantation: importance of viral transmission from the donor. Clin Infect Dis 2003; 37: 606-607.
30. Kantor R, Mayan H, Shalmon B, et al. Kaposi's sarcoma after lung transplantation in a Sephardic Jewish woman. Dermatology 2000; 200(1): 49-50.
31. Shmueli D, Shapira Z, Yussim A, et al. The incidence of Kaposi sarcoma in renal transplant patients and its relation to immunosuppression. Transplant Proc 1989; 21(1 Pt 3): 3209-3210.
32. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77(5): 760-762.
33. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352(13): 1371-1373.
34. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306(15): 913-918.
35. Wigle DA, Chaparro C, Humar A, et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72(11): 1783-1786.
36. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176(6): 1462-1467.
37. Hachem RR, Chakinala MM, Yusen RD, et al. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation 2004; 77(3): 431-437.
38. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323(25): 1723-1728.
39. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116(5): 1273-1277.
40. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15(6): 647-656.
41. Rappaport DC, Chamberlain DW, Shepherd FA, et al. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206(2): 519-524.
42. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154(6 Pt 1): 1712-1717.
43. Paranjothi S, Yusen RD, Kraus MD, et al. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20(10): 1054-1063.
44. Cohen AH, Sweet SC, Mendeloff E, et al. High incidence ot posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1252-1255.
45. Montone KT, Litzky LA, Wurster A, et al. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996; 119(5): 544-551.
46. Caillard S, Lachat V, Moulin B. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. Transpl Int 2000; 13 Suppl 1: S388-393.
47. Cosio FG, Nuovo M, Delgado L, et al. EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD. Am J Transplant 2004; 4(1): 116-123.
48. Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340(18): 1390-1397.